![]() |
![]() |
|||||
The CompanyIt is Sangui BioTech's mission to develop innovative pharmaceuticals and medical products serving the biological regeneration of cells through compensatory supply of vital substrates to the human body. Oxygen, in this respect is of paramount importance. In pursuit of these goals, Professor Wolfgang K. Barnikol established the first Sangui Company in Mainz, Germany, in 1995. At that time, two main projects had evolved from his earlier university and publicly funded studies:
In order to obtain additional funding, in 1997 the company underwent a restructuring in the event of which Sangui BioTech International, Inc., a Colorado company, emerged (Certificate of Good Standing). As the parent company of the operating SanguiBioTech GmbH of Witten, Germany, it is traded on the electronic securities trading platform www.pinksheets.com (symbol: SGBI), as well as on the OTC market in Hamburg (WKN: 906757). Like most biotech companies, Sangui BioTech International met increasing difficulties to address the capital market for additional funding after the decline of the markets since 2001. Unlike some biotech companies Sangui has been able to refocus its activities on products which promised to be marketable in the short term. These include:
Reminder: This company portrait as well as the other remarks on this website should be considered but a brief overview which should not serve as the basis for an investment decision. For more detailed information about the risks and opportunities related to our business please refer to our news & reports pages, in particular to our annual and quarterly reports.
|
||||||